Business Daily – Are Weight-Loss Drugs Reshaping Business?

Host: Hannah Mullane, BBC World Service
Date: March 4, 2026
Episode Focus: The ripple effects of the booming weight-loss drug market—especially GLP1 medications like Ozempic, Wegovy, and Mounjaro—on a wide spectrum of industries from food and fitness to pharmaceuticals and economics.

Episode Overview

This episode, the final in a three-part series, investigates how the surge in popularity of new weight-loss drugs is transforming business sectors. The discussion spans food manufacturing, consumer spending, fitness trends, and the global economics of obesity, guided by interviews with industry insiders and experts.

Key Topics & Insights

1. The Rise and Reach of GLP1 Weight-Loss Drugs

Timestamps: 01:26–02:19

• Drugs such as Ozempic, Wegovy, and Mounjaro, originally intended for diabetes management, have created explosive demand due to their rapid and significant weight-loss results.
• Users regularly report significant and sustained results:
  • Tammy: "I've lost over 32% of my body weight." (02:19)
  • Anonymous: "My first dose of Wegovy, I'm at maintenance, 50 pound down." (02:42)
• Quote, Gabe Zickerman:
  “For anybody considering entering the food business today, if GLP1 support is not core to your business plan, you know, I don't know what your business plan is.” (02:10)

2. The Food Industry’s GLP1 Pivot

Timestamps: 03:33–08:42

Interview: Gabe Zickerman, Founder of Two Scoops (LA-Based Ice Cream)

• Zickerman explains Two Scoops’ focus: protein-rich, zero-sugar dessert options designed specifically for people on GLP1 medications.

  • “Our sort of mission is to…make dessert that’s better for you, but doesn’t taste like some kind of science experiment. That’s just pure sadness.” (03:33)

• Two Scoops products emphasize:

  • High protein (30g per pint)
  • No added sugar (uses allulose, a non-glycemic sweetener that may boost GLP1 production)
  • Reformulated inclusions (e.g., zero-sugar, high-protein marshmallow fluff)

• Industry Ripple Effects:

  • Major brands are entering the space:
    • Nestlé launched Vital Pursuit (GLP1-friendly frozen foods).
    • Conagra Brands labels “GLP1 friendly” on Healthy Choice offerings.
    • Danone is developing products for GLP1 users.

• Quote:
  “GLP1s are going to change absolutely everything about the food business...there’s going to be even more demand for protein supplementation, sugar reduction...and better quality foods.” – Gabe Zickerman (05:42)

Economics of Change

• Portion sizes are decreasing, protein content is increasing, costs are going up.
• Zickerman emphasizes that for users, sustained, lifelong medication is attractive if the drug continues to work and has tolerable side effects:
  • “I don’t care about going off this medicine…This medicine works. This medicine has changed my life.” (07:19)

3. The Global Economics of Obesity

Timestamps: 09:25–10:34; 16:34–18:33

Expert: Sandra Barboso, Health Economist (ITIF)

• Obesity is both a health and economic crisis:

  • US: Over 42% adults obese (140+ million), $173B annual healthcare costs, 4% reduction in GDP.
  • Global: Nearly 40% overweight or obese; projected to exceed 50% by 2035 with $4T in costs.

• Quote:
  “The costs don’t just come from treating obesity...but also from lost productivity because people who are obese take more sick days, have reduced performance at work, and they also leave the workforce earlier…” (09:25)

• Current GLP1 drug costs are high (Ozempic ~$1,000/month in the US; $300+ with insurance), but the upcoming expiration of patents and introduction of generics could decrease prices by 80% or more, expanding accessibility globally.

• Past drug analogies (e.g., Sovaldi for Hepatitis C) suggest cost reductions and increased uptake in coming years.

4. Shifts in Consumer Spending & Lifestyle

Timestamps: 11:42–12:57

• JP Morgan reports a 17% drop in supermarket spending among GLP1 users in the first six months.
• Walmart’s CEO observes customers buying fewer high-calorie products.
• Health and fitness book sales slide by 15% since drug introduction (Sakana Research).
• Exercise spending remains robust or increases, with users motivated to maintain or build muscle alongside weight loss.

5. Fitness Industry Adaptation: Case Study—Lifetime Health Clubs

Timestamps: 12:57–16:12

Interview: Jim Laval, Chief Science Officer (Lifetime)

• Lifetime’s “Miora” clinics offer medication and support alongside traditional gym programs.

• Client retention is high (>95%), signaling satisfaction with integrated medication & lifestyle changes.

• Laval frames responsible GLP1 use as empowering for those who previously struggled:

  • “There’s people that exercise, they diet, they do everything that they think is right and they don’t lose a pound, and that’s because their metabolism is already somewhat broken.” (12:57)

• Responds to skepticism from the fitness world:

  • “Utilizing [GLP1s] in a way that empowers people to make change is...an absolute must in our world today.” (14:31)

• Business implication: Premium memberships ($150–$400/month) plus program and medication fees; current cost restricts access but may change with generics.

Notable Quotes & Memorable Moments

• Gabe Zickerman, on food industry evolution:
  “If GLP1 support is not core to your business plan, you know, I don’t know what your business plan is.” (02:10)

• Sandra Barboso, on the cost-benefit of treatment:
  “They’re expensive today, but not treating obesity is far costlier.” (16:34)

• Jim Laval, on clinical frustration:
  “I think it more becomes a problem with people that criticize it is...why are you so afraid to empower people to make a change?” (14:31)

Important Segment Timestamps

• 01:26 – Introduction of GLP1 medicines & market context
• 03:33 – Interview with Gabe Zickerman, food industry angle
• 05:32 – Changing ingredients and product formulations
• 09:25 – Obesity as an economic issue (Sandra Barboso)
• 11:42 – Consumer spending shifts, impact on supermarkets and books
• 12:57 – Interview with Jim Laval, GLP1 in fitness sector
• 16:34 – Future affordability, generics on the horizon
• 18:33 – Projections: $150B global GLP1 market by 2035

Conclusion

Weight-loss jabs are reshaping everything from how global food giants design product lines to what consumers spend at grocery stores and gyms. While cost and access remain current obstacles, market shifts and patent expirations are poised to democratize these medicines. The food and fitness industries are pivoting quickly, and a vast new economy is emerging—one where GLP1-friendly options and holistic health approaches are fast becoming not just a trend, but a business necessity.